Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program

Future Cardiol. 2016 Jul;12(4):405-18. doi: 10.2217/fca-2016-0028. Epub 2016 May 10.


Ticagrelor (P2Y12 receptor antagonist) is presently indicated for preventing atherothrombotic events in patients with acute coronary syndrome and patients with a history of myocardial infarction. The PARTHENON clinical development program comprises five randomized, controlled, cardiovascular, indication-seeking outcome studies, aiming to evaluate ticagrelor across the spectrum of patients with atherothrombotic disease. Results of two large-scale trials support a benefit for ticagrelor in patients with acute coronary syndrome (PLATO; ClinicalTrials.gov: NCT00391872) and in patients with a history of myocardial infarction (PEGASUS-TIMI 54; ClinicalTrials.gov: NCT01225562). Ongoing trials will provide information on the efficacy and safety of ticagrelor in patients with acute ischemic stroke or transient ischemic attack (SOCRATES; ClinicalTrials.gov: NCT01994720), peripheral artery disease (EUCLID; ClinicalTrials.gov: NCT01732822) and coronary artery disease in patients with Type 2 diabetes mellitus (THEMIS: ClinicalTrials.gov: NCT01991795).

Keywords: P2Y12 receptor antagonist; acute coronary syndrome; atherosclerosis; coronary artery disease; diabetes mellitus; ischemic stroke; myocardial infarction; ticagrelor.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / complications*
  • Adenosine / analogs & derivatives*
  • Adenosine / therapeutic use
  • Atherosclerosis / drug therapy*
  • Diabetes Mellitus, Type 2 / complications
  • Humans
  • Myocardial Infarction / complications
  • Purinergic P2Y Receptor Antagonists / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Ticagrelor
  • Treatment Outcome


  • Purinergic P2Y Receptor Antagonists
  • Ticagrelor
  • Adenosine

Associated data

  • ClinicalTrials.gov/NCT01994720
  • ClinicalTrials.gov/NCT01225562
  • ClinicalTrials.gov/NCT00391872
  • ClinicalTrials.gov/NCT01732822
  • ClinicalTrials.gov/NCT01991795